JP2005526511A - ワクチン - Google Patents

ワクチン Download PDF

Info

Publication number
JP2005526511A
JP2005526511A JP2004506720A JP2004506720A JP2005526511A JP 2005526511 A JP2005526511 A JP 2005526511A JP 2004506720 A JP2004506720 A JP 2004506720A JP 2004506720 A JP2004506720 A JP 2004506720A JP 2005526511 A JP2005526511 A JP 2005526511A
Authority
JP
Japan
Prior art keywords
muc
nucleic acid
vntr
sequence
acid molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004506720A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005526511A5 (https=
Inventor
バーデン，ネイル
ハンブリン，ポール
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of JP2005526511A publication Critical patent/JP2005526511A/ja
Publication of JP2005526511A5 publication Critical patent/JP2005526511A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4727—Mucins, e.g. human intestinal mucin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
JP2004506720A 2002-05-24 2003-05-23 ワクチン Pending JP2005526511A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0212036.8A GB0212036D0 (en) 2002-05-24 2002-05-24 Vaccines
PCT/EP2003/005595 WO2003099193A2 (en) 2002-05-24 2003-05-23 Vaccines

Publications (2)

Publication Number Publication Date
JP2005526511A true JP2005526511A (ja) 2005-09-08
JP2005526511A5 JP2005526511A5 (https=) 2006-06-08

Family

ID=9937387

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004506720A Pending JP2005526511A (ja) 2002-05-24 2003-05-23 ワクチン

Country Status (7)

Country Link
US (1) US20060062798A1 (https=)
EP (1) EP1507861A2 (https=)
JP (1) JP2005526511A (https=)
AU (1) AU2003237701A1 (https=)
CA (1) CA2485733A1 (https=)
GB (1) GB0212036D0 (https=)
WO (1) WO2003099193A2 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0212046D0 (en) * 2002-05-24 2002-07-03 Glaxo Group Ltd Vaccines
GB0304634D0 (en) * 2003-02-28 2003-04-02 Glaxo Group Ltd Vaccines
JP5060134B2 (ja) * 2003-12-12 2012-10-31 ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ・アズ リプレゼンテッド バイ ザ セクレタリー・デパートメント オブ ヘルス アンド ヒューマン サービシーズ ヒト細胞傷害性Ｔリンパ球のエピトープ及びそのＭＵＣ−１の非ＶＮＴＲ（ｎｏｎ−ｖａｒｉａｂｌｅｎｕｍｂｅｒｏｆｔａｎｄｅｍｒｅｐｅａｔｓｅｑｕｅｎｃｅ）由来のアゴニストエピトープ
CA2595778A1 (en) * 2005-01-28 2006-08-03 Ramot At Tel Aviv University, Ltd. Anti-muc1 .alpha..beta. antibodies
US9140692B1 (en) * 2010-01-08 2015-09-22 Glycozym, Inc. Methods of identifying glycopeptides recognized by disease-associated auto-antibodies

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744144A (en) * 1993-07-30 1998-04-28 University Of Pittsburgh University Patent Committee Policy And Procedures Synthetic multiple tandem repeat mucin and mucin-like peptides, and uses thereof
AUPM322393A0 (en) * 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
US6548643B1 (en) * 1994-11-16 2003-04-15 Austin Research Institute Antigen carbohydrate compounds and their use in immunotherapy
EP1012276A2 (en) * 1997-02-24 2000-06-28 Therion Biologics Corporation Recombinant pox virus for immunization against muc1 tumor-associated antigen
IL125608A0 (en) * 1998-07-30 1999-03-12 Yeda Res & Dev Tumor associated antigen peptides and use of same as anti-tumor vaccines
US6228843B1 (en) * 1999-04-23 2001-05-08 University Technology Corporation Method of using PKC inhibiting compounds to treat vascular disease
JP2003510094A (ja) * 1999-09-08 2003-03-18 トランジェーヌ、ソシエテ、アノニム Ｍｕｃ−１由来のペプチド
GB9930359D0 (en) * 1999-12-22 2000-02-09 Glaxo Group Ltd Novel polypeptides
EP1257565A4 (en) * 2000-02-01 2005-04-06 Austin Research Inst DERIVED FROM MUCIN-1 ANTIGENE AND ITS USE IN IMMUNOTHERAPY
US7125663B2 (en) * 2001-06-13 2006-10-24 Millenium Pharmaceuticals, Inc. Genes, compositions, kits and methods for identification, assessment, prevention, and therapy of cervical cancer
GB0212046D0 (en) * 2002-05-24 2002-07-03 Glaxo Group Ltd Vaccines

Also Published As

Publication number Publication date
CA2485733A1 (en) 2003-12-04
WO2003099193A3 (en) 2004-02-19
WO2003099193A2 (en) 2003-12-04
US20060062798A1 (en) 2006-03-23
AU2003237701A1 (en) 2003-12-12
GB0212036D0 (en) 2002-07-03
AU2003237701A8 (en) 2003-12-12
EP1507861A2 (en) 2005-02-23

Similar Documents

Publication Publication Date Title
US8114405B2 (en) Cancer vaccine based on brother of regulator of imprinted sites molecule (BORIS)
JP5416968B2 (ja) 癌細胞及び腫瘍間質上に発現される優勢及び亜優勢エピトープに対する多価免疫応答を誘発するための方法及び組成物
JP2004527213A (ja) 抗原に小胞体シャペロンポリペプチドを連結した分子ワクチン
CN100408682C (zh) 具有数目减少的vntr重复单位的muc-1抗原
WO2019101062A9 (zh) 重组疫苗及其应用
JP2002528519A (ja) 抗腫瘍効果を有する、抗原性タンパク質をコードしているｄｎａを含む医薬組成物
JP2005526511A (ja) ワクチン
EP1240317B1 (en) Nucleic acid vaccination
US20060147458A1 (en) Vaccines
JP2007505601A (ja) ワクチン
JPWO2003000894A1 (ja) ポリヌクレオチドワクチン
US8921534B2 (en) Enhancement of the immune response using CD36-binding domain
WO2024222886A1 (zh) 一种针对MICA/B靶点的mRNA肿瘤疫苗

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060412

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060412

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090428

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090722

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090729

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100105